

1 **Type of Issue** Initial Public Offer

2 **Issue Size (Rs. Mn)** 8,402.67

*Source: Prospectus

3 **Grade of issue along with name of the rating agency**

Name NA
Grade NA

4 **Subscription Level (Number of times)** 5.97*

* Figure is prior to rejections

Source: Minutes for basis of allotment dated October 30, 2023

5 **QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges**

Particulars	%age
(i) On Allotment **	7.00%
(ii) at the end of the 1st Quarter immediately after the listing of the issue (December 31, 2023)	6.63%
(iii) at the end of 1st FY (March 31, 2024)	5.04%
(iv) at the end of 2nd FY (March 31, 2025)	3.62%
(v) at the end of 3rd FY (March 31, 2026)	5.39%

**Basis of Allotment

^Holding of institutions category as disclosed to Stock Exchanges

6 **Financials of the issuer**

Parameters	(Rs. Million)		
	1st FY (March 31,2024)	2nd FY (March 31,2025)	3rd FY (March 31,2026)
Income from operations	7,115.98	10,300	9,473
Net Profit for the period	1,637.51	3,052	2,478
Paid-up equity share capital	346.93	346.93	347
Reserves excluding revaluation reserves	8,105.30	10,984	13,252

7 **Trading Status**

The equity shares of Bluejet Healthcare Limited were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") in November 2023

The equity shares have not been suspended or delisted.

Particulars	Status
(i) at the end of 1st FY (March 31, 2024)	Frequently traded
(ii) at the end of 2nd FY (March 31, 2025)	Frequently traded
(iii) at the end of 3rd FY (March 31, 2026)*	Actively Trading

* Trading status not disclosed as the relevant fiscal year has not completed.

Source: Stock exchange data.

8 **Change in Directors of Issuer from the disclosures in the offer document**

Particulars	Name of Director	Appointed / Resigned
(i) at the end of 1st FY (March 31, 2024)	-	-
(ii) at the end of 2nd FY (March 31, 2025)	Priyanka Yadav	Appointed
	Popat Bhagwan Kedar	Appointed
	Girish Paman Vanvari	Appointed
(iii) at the end of 3rd FY (March 31, 2026)	Divya Sameer Momaya	Appointed
	Preeti Gautam Mehta	Appointed

9 **Status of implementation of project/ commencement of commercial production**

(i) as disclosed in the offer document Not applicable as 100% offer for sale

(ii) Actual implementation Not applicable

(iii) Reasons for delay in implementation, if any Not applicable

10 **Status of utilization of issue proceeds**

(i) As disclosed in the offer document Not applicable as 100% offer for sale

(ii) Actual utilization Not applicable

(iii) Reasons for deviation, if any Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds	Not applicable
(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document	Not applicable
(iii) Any other reservations expressed by the monitoring agency about the end use of funds	Not applicable

12 Pricing Data

Designated Stock Exchange	NSE
Issue Price (Rs.)	346.00
Listing Date	1-Nov-23

Price parameters	At close of listing day- November 1, 2023	Close of 30th calendar day from listing day (i.e. Nov 30, 2023)	Close of 90th calendar day from listing day (i.e. Jan 29, 2024)	As at the end of the 1st FY after the listing of the issue (31st March, 2024)		
				Closing price	High	Low
Market Price	413.40	360.10	380.95	382.90	411.90	324.00
NIFTY 50*	18,989.15	20,133.15	21,737.60	22,326.90	22,493.55	17,599.15
Sector Index [#]	9,293.20	10,289.45	11,167.40	12,059.30	12,159.00	7,727.00

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2025)			As at the end of the 3rd FY after the listing of the issue (31st March, 2026)		
	Closing price	High	Low	Closing price	High	Low
Market Price	884.85	968.30	534.00	327.25	1,027.80	325.00
Nifty 50*	23,519.35	26,277.35	21,281.45	22,331.40	26,373.20	21,743.65
Sector Index [#]	13,681.30	14,899.90	11,625.45	14,201.05	15,148.75	12,565.40

* Being index of NSE, the designated stock exchange

Nifty Healthcare Index

13 Basis for Issue Price

Accounting ratio		As disclosed in offer document, at the end of FY 2023*	At the end of 1st FY (March 31, 2024)	At the end of 2nd FY (March 31, 2025)	At the end of 3rd FY (March 31, 2026)
EPS (Diluted)	Company				
	Consolidated	9.23	9.44	17.59	14.29
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
P/E	Company				
	Consolidated	37.49	40.56	50.30	22.90
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
RoNW	Company				
	Consolidated	23.48%	19.37%	26.93%	18.22%
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable
NAV per share	Company				
	Consolidated	39.29	48.73	65.32	78.40
	Peer Group	Not Applicable	Not Applicable	Not Applicable	Not Applicable

Notes

* Sourced from Prospectus dated October 27, 2023

14 Any other material information

Particulars	Date
Company has informed that a fire incident occurred on the morning of 03rd November 2023 at Company's Mahad plant situated at K-4/1, Mahad Industrial area Mahad, Maharashtra .	03-Nov-23
Company has informed that till date i.e November 5, 2023 there have been seven casualties and the Company's first priority as of now is to take care of the safety and well-being of the impacted employees and their family. Company team is working & co-operating with the state and local authorities to restore normalcy in the	05-Nov-23
Company has informed that the Company has received an order by Maharashtra Pollution Control Board ("MPCB") vide letter dated November 7, 2023 issuing closure direction at one of our units at Mahad MIDC under Water (Prevention & Control Pollution) Act, 1974 and Air (Prevention & Control Pollution) Act, 1984.	09-Nov-23
Company has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor	26-May-24

Company has informed that in connection with the fire incident occurred on the morning of 03rd November 2023 at Company's Mahad plant situated at K-4/1, Mahad Industrial area Mahad, Maharashtra, Maharashtra Pollution Control Board has imposed environmental compensation of Rs. 3,91,875/-, forfeit of a bank guarantee of Rs. 5,00,000/- and a direction to submit the B.G of Rs. 10,00,000/- as preconditions to conditional restart of production.	04-Sep-24
Company has informed that they have received the consent dated 13 November, 2024 to operate under Section 26 of the Water (Prevention & Control of Pollution) Act, 1974 & under Section 21 of the Air (Prevention & Control of Pollution) Act, 1981 and Authorization under Rule 6 and Rule 18(7) of the Hazardous & Other Wastes (Management & Transboundary Movement) Rules 2016 for Company's Unit no3 at Mahad, Maharashtra.	15-Nov-24
Company has informed the Exchange about Change in Directors	19-Nov-24
Company has informed that Blue Jet Healthcare Limited at the Company's existing Unit 2 facility situated at Ambernath, Maharashtra, India, has successfully completed commissioning of production block to manufacture Advance Contrast Media on December 9, 2024	10-Dec-24
The Board has approved investments of upto Rs 40 Crores for setting up of Research and Development Facility	29-Jan-25
The Company notified the exchange about receipt of assessment orders and demand notices from the Income Tax Department under Section 156 of the Income Tax Act, 1961 ('the Act') essentially on account of disallowance of depreciation on goodwill in the Assessment year 2020-21 and disallowance of subsequent set-off of unabsorbed depreciation allowance. In this regard, the Company has filed an appeal before the Joint Commissioner (Appeals) /Commissioner of Income-tax (Appeals) Mumbai for the AYs 2020-21, 2021-22 & 2022-23 on March 31, 2025, pertaining to above demand.	01-Apr-25
The Board of Directors approved the following - a final dividend of Rupees 1.2 (60%) per Equity Share of the face value of Rs.2 each (Rupees Two only) for the Financial Year ended March 31, 2025. The Final Dividend is subject to the approval of the members at the ensuing Annual General Meeting which will be held within stipulated timeline as per the provisions of the Companies Act, 2013. Proposal for raising of funds of up to ₹15,000 million by way of creation, offering and issuance of any instrument or security for cash, with or without green shoe option, including fully paid-up Equity Shares, fully or partly convertible debentures, any other equity based instruments or securities, convertible preference shares of any kind or type, any other financial instruments/ securities convertible into and/or linked to Equity Shares (including warrants (detachable or not), or otherwise, in registered or bearer form) (collectively "Securities") or combination of any of the aforementioned Securities Appointment of Ms. Payal Gandhi, Chief Business Strategy Officer as Senior Management Personnel of the Company w.e.f. June 1, 2025. Acquisition of a plot located at Dahej III, Industrial Estate Gujarat, measuring 30,366.32 square meters from the Gujarat Industrial Development Corporation (GIDC), for manufacturing purpose, in line with the business objectives of the company. The Agreement will be executed in due course.	14-May-25
To consider and approve raising of funds in one or more tranches, by issuance of Equity Shares and/or other Eligible Securities	16-Jun-25
Approved the proposal for acquisition of an industrial land parcel and related investment at the new manufacturing site.	31-Jul-25
Fixed record date for dividend as September 19, 2025	22-Aug-25
Notice of Offer for Sale of Shares by Promoter & Floor Price	09-Sep-25
Intimation of sale of share by Mr. Akshay B. Arora, promoter of the Company	12-Sep-25
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Akshay Bansarilal Arora	15-Sep-25
Company has successfully gone live with launch of 1.0 of SAP S/4HANA as part of a major business digital transformation initiative called "PROJECT LEAP".	09-Dec-25
Groundbreaking ceremony for a new plot at Andhra Pradesh	19-Feb-26
Blue Jet Healthcare Limited has informed the Exchange regarding a press release dated February 28, 2026, titled "Company Update".	28-Feb-26
Akshay Bansarilal Arora has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.	02-Apr-26
Blue Jet Healthcare Limited has informed the Exchange that Board of Directors at its meeting held on May 25, 2026, recommended Final Dividend of Rs. 1.20 per equity share.	25-May-26
Blue Jet Healthcare Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on Jun 17, 2026	26-May-26
Blue Jet Healthcare Limited has informed the Exchange about Copy of Newspaper Publication for Extra Ordinary General Meeting to be held on 17th June, 2026	27-May-26

Source: NSE and BSE website

Note: The Company meets Investors/ Analysts/ Participants from time to time. Please refer to the website of the Stock Exchanges for the intimation of the schedule of such meetings and related details, For further updates and information, please refer to the website of the Stock Exchanges i.e. www.bseindia.com and / or www.nseindia.com.